Baseline characteristics of patients.

Baseline characteristics of patients.

<div><p>Purpose</p><p>To evaluate idiopathic epiretinal membrane (iERM) area changes and the association with visual function in patients with good vision, using confocal scanning laser ophthalmoscopy (cSLO).</p><p>Methods</p><p>The medical records of...

Full description

Saved in:

Bibliographic Details
Main Author:	Su Hwan Park (15158181) (author)
Other Authors:	Sangwoo Moon (15401423) (author), Su-Jin Kim (90561) (author), Ji-Eun Lee (782090) (author), Sung Who Park (17930749) (author), Iksoo Byon (18462135) (author), Seung Min Lee (1644409) (author)
Published:	2025
Subjects:	Medicine Cell Biology Infectious Diseases corrected visual acuity larger bcva change every 6 months predicting vision loss erm area reduction erm area visual function bcva reduction 6 months vision loss good vision area changes xlink "> univariate analysis significant predictor short axes reviewed retrospectively optimal cutoff odds ratio medical records diagonal lengths 010 ). 002 ). &# 8805
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of changes in ERM areas and lengths between the two groups at baseline and final follow-up.
by: Su Hwan Park (15158181)
Published: (2025)

Univariate analysis of the total ERM area in relation to significant vision loss.
by: Su Hwan Park (15158181)
Published: (2025)

Simple and multiple linear regression analyses between clinical factors and visual acuity change at final follow-up.
by: Su Hwan Park (15158181)
Published: (2025)

Comparison of ERM areas and lengths between the two groups at the final follow-up.
by: Su Hwan Park (15158181)
Published: (2025)

Receiver operating characteristic curve for predicting 24-month vision loss using the total area reduction ratio at 6-month follow-up.
by: Su Hwan Park (15158181)
Published: (2025)

Representative cases showing changes in the epiretinal membrane (ERM) area.
by: Su Hwan Park (15158181)
Published: (2025)

Changes in best-corrected visual acuity and total area reduction ratio of the epiretinal membrane (ERM) during follow-up.
by: Su Hwan Park (15158181)
Published: (2025)

Data.
by: Su Hwan Park (15158181)
Published: (2025)

Multiple regression analysis between postoperative best-corrected visual acuity (BCVA) and preoperative BCVA and OCT findings in epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH).
by: Noriko Kubota (11915648)
Published: (2025)

Relationships between preoperative OCT findings and visual acuity in epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH).
by: Noriko Kubota (11915648)
Published: (2025)

OCT findings of epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH).
by: Noriko Kubota (11915648)
Published: (2025)

Clinical characteristics of epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH).
by: Noriko Kubota (11915648)
Published: (2025)

Comparison of central foveal thickness (CFT) (A), central retinal thickness (CRT) (B), and macular volume (MV) (C) in epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH) Both the CFT and CRT were significantly higher in the ERM compared to the other three groups.
by: Noriko Kubota (11915648)
Published: (2025)

Best-corrected visual acuity (BCVA) before and after surgery in epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH). a: Significantly different in the Wilcoxon’s signed-rank test. b: Significantly different in the Tukey-Kramer test.
by: Noriko Kubota (11915648)
Published: (2025)

Comparison of axial length (A) and spherical equivalent (B) in epiretinal membrane (ERM), macular pseudohole (MPH), ERM-foveoschisis (ERM-FS) and lamellar macular hole (LMH).
by: Noriko Kubota (11915648)
Published: (2025)

Raw data for all parameters.
by: Noriko Kubota (11915648)
Published: (2025)

Baseline demographics and clinical characters of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye.
by: Mike Y. Chen (13881956)
Published: (2025)

Outcomes of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye who have received aflibercept 2mg injections only.
by: Mike Y. Chen (13881956)
Published: (2025)

Standard Least Square Model of BCVA at different time points.
by: Mike Y. Chen (13881956)
Published: (2025)

Outcomes of patients from restricted (Group 1) and non-restricted (Group 2) COVID-19 period with newly diagnosed nAMD of the first eye.
by: Mike Y. Chen (13881956)
Published: (2025)

Minimum data set.
by: Mike Y. Chen (13881956)
Published: (2025)

Epidemiological data at baseline.
by: Isabel B. Pfister (4348285)
Published: (2024)

Change in visual acuity (VA, in ETDRS letters) compared to baseline, stratified by baseline VA (Decimal BCVA <0.2; 0.25–0.5; >0.5).
by: Isabel B. Pfister (4348285)
Published: (2024)

Results of the multiple linear regression analyses including different predictors for long-term visual acuity (with visual acuity at baseline as control).
by: Isabel B. Pfister (4348285)
Published: (2024)

Univariate regression analysis of prognostic parameters possibly predicting long term visual acuity.
by: Isabel B. Pfister (4348285)
Published: (2024)

Presence of retinal fluid during the treatment period up to 5 years of follow up.
by: Isabel B. Pfister (4348285)
Published: (2024)

Changes in central retinal thickness (CRT) during the treatment period up to 5 years of follow up.
by: Isabel B. Pfister (4348285)
Published: (2024)

Visual acuity over time stratified by the presence of macular atrophy after the 1<sup>st</sup> year (MA).
by: Isabel B. Pfister (4348285)
Published: (2024)

Visual acuity over time stratified by the presence of intraretinal fluid (IRF) after the 1<sup>st</sup> year.
by: Isabel B. Pfister (4348285)
Published: (2024)

Treatment interval distribution.
by: Isabel B. Pfister (4348285)
Published: (2024)

Multivariable logistic regression analysis of characteristics of age and baseline BCVA associated with loss to follow-up.
by: Takaaki Sugisawa (13417212)
Published: (2025)

The distribution of age, baseline BCVA and nAMD subtype for loss to follow-up between 3 months, 1 year, and 2 years after treatment initiation.
by: Takaaki Sugisawa (13417212)
Published: (2025)

<b>Podcast extender of the Manuscript:</b> Functional endpoints in patients with geographic atrophy: What to consider when designing a clinical trial
by: Christiana Dinah (10131056)
Published: (2025)

Comparison of the reasons for loss to follow-up at 3 months, 1 year, and 2 years after treatment initiation.
by: Takaaki Sugisawa (13417212)
Published: (2025)

Characteristics of patients with neovascular age-related macular degeneration who were lost to follow-up and those of patients who continued follow-up for 2 years after initiating anti-VEGF treatment.
by: Takaaki Sugisawa (13417212)
Published: (2025)

Characteristics of patients with neovascular age-related macular degeneration who were lost to follow-up and those of patients who continued follow-up for one year after initiating anti-VEGF treatment.
by: Takaaki Sugisawa (13417212)
Published: (2025)

Characteristics of patients with neovascular age-related macular degeneration who were lost to follow-up and those of patients who continued follow-up for 3 months after initiating anti-VEGF treatment.
by: Takaaki Sugisawa (13417212)
Published: (2025)

Patients’ inclusion period for analyzing follow-up status for up to 3 months, 3 months to 1 year, and 1 year to 2 years.
by: Takaaki Sugisawa (13417212)
Published: (2025)

Baseline characteristics.
by: Seung Min Lee (1644409)
Published: (2025)

Comparison between eyes with and without visual gain of 3 lines or more.
by: Seung Min Lee (1644409)
Published: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ksgubpckes6ules8p9861a387i